You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Reassurance, Refunds & Replacements

If your product does not perform as described on this datasheet, we will refund or replace your product...

Read our guarantee »
 

Anti-EPO Receptor antibody [MM-0031-6G7] (ab56310)

CodeSizePriceAbpointsAvailability
    
 
  • -
  •   
  •   
  •   
  •  
  •   
  •   
Updating...

Overview

Product name

Anti-EPO Receptor antibody [MM-0031-6G7]
See all EPO Receptor products (7) ...

Description

Mouse monoclonal [MM-0031-6G7] to EPO Receptor

Specificity

Ab56310 recognizes EPO Receptor using western blot. This antibody has been tested to be able to pick up human EPOR around 60-65 kDa under both reducing and non-reducing conditions. However the immunosignal is much stronger under non-reducing conditions so remove beta-mercaptoethanol or DTT from sample buffer.

Tested applications

IHC-P, WB, Flow Cytmore details

Cross reactivity

Reacts with

Human

Immunogen

Human recombinant EPO Receptor (extracellular domain)

Properties

Form

Lyophilised:
Reconstitute with 0.5ml sterile PBS

Storage instructions

Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

Storage buffer

Preservative: None
Constituents: PBS

Concentration

Concentration information loading...

Purity

Protein G purified

Clonality

Monoclonal

Clone number

MM-0031-6G7

Isotype

IgG2a

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - EPO Receptor antibody [MM-0031-6G7] (ab56310)Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - EPO Receptor antibody [MM-0031-6G7] (ab56310) image (enlarge)

Applications

Show applications key

Our Abpromise guarantee covers the use of ab56310 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • ShowHide1 Image

    IHC-P

     IHC-P: 1/10 - 1/40.(Prot...Read more →

    IHC-P: 1/10 - 1/40.(Proteinase k digestion is required, 20 ug/ml proteinase K (in PBS), digestion at room temperature for 15-30 mins.)

  • ShowHide

    WB

     WB: 1/1000 - 1/2000. Use...Read more →

    WB: 1/1000 - 1/2000. Use under non reducing condition. Detects a band of approximately 60 kDa (predicted molecular weight: 55 kDa).

  • ShowHide

    Flow Cyt

     Flow Cyt: Use at an assa...Read more →

    Flow Cyt: Use at an assay dependent concentration. (PubMed: 21698228)

Target

Function

Receptor for erythropoietin. Mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate the LYN tyrosine kinase.
Isoform EPOR-T acts as a dominant-negative receptor of EPOR-mediated signaling.

Tissue specificity

Erythroid cells and erythroid progenitor cells. Isoform EPOR-F is the most abundant form in EPO-dependent erythroleukemia cells and in late-stage erythroid progenitors. Isoform EPOR-S and isoform EPOR-T are the predominant forms in bone marrow. Isoform EPOR-T is the most abundant from in early-stage erythroid progenitor cells.

Involvement in disease

Defects in EPOR are the cause of erythrocytosis familial type 1 (ECYT1) [MIM:133100]. ECYT1 is an autosomal dominant disorder characterized by increased serum red blood cell mass, elevated hemoglobin and hematocrit, hypersensitivity of erythroid progenitors to erythropoietin, erythropoietin low serum levels, and no increase in platelets nor leukocytes. It has a relatively benign course and does not progress to leukemia.

Sequence similarities

Belongs to the type I cytokine receptor family. Type 1 subfamily.
Contains 1 fibronectin type-III domain.

Domain

The WSXWS motif appears to be necessary for proper protein folding and thereby efficient intracellular transport and cell-surface receptor binding.
The box 1 motif is required for JAK interaction and/or activation.
Contains 1 copy of a cytoplasmic motif that is referred to as the immunoreceptor tyrosine-based inhibitor motif (ITIM). This motif is involved in modulation of cellular responses. The phosphorylated ITIM motif can bind the SH2 domain of several SH2-containing phosphatases.

Post-translational
modifications

On EPO stimulation, phosphorylated on C-terminal tyrosine residues by JAK2. The phosphotyrosine motifs are also recruitment sites for several SH2-containing proteins and adapter proteins which mediate cell proliferation. Phosphorylation on Tyr-454 is required for PTPN6 interaction, Tyr-426 for PTPN11. Tyr-426 is also required for SOCS3 binding, but Tyr-454/Tyr-456 motif is the preferred binding site.
Ubiquitinated by NOSIP; appears to be either multi-monoubiquitinated or polyubiquitinated. Ubiquitination mediates proliferation and survival of EPO-dependent cells.

Cellular localization

Cell membrane and Secreted. Secreted and located to the cell surface.

Target information above from: UniProt accessionP19235 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).

Information by UniProt

Alternative names

  • EPO R antibody
  • EPO-R antibody
  • epor antibody
  • EPOR_HUMAN antibody
  • Erythropoietin receptor antibody
  • Erythropoietin receptor precursor antibody
see all

Anti-EPO Receptor antibody [MM-0031-6G7] images:

  Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - EPO Receptor antibody [MM-0031-6G7] (ab56310)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - EPO Receptor antibody [MM-0031-6G7] (ab56310)

Formalin fixed and Paraffin embedded human placenta tissue section was subjected to IHC staining using ab56310 (Proteinase K pretreatment is required).

References for Anti-EPO Receptor antibody [MM-0031-6G7] (ab56310)

This product has been referenced in:

  • Chen AYet al. Productive Parvovirus B19 Infection of Primary Human Erythroid Progenitor Cells at Hypoxia Is Regulated by STAT5A and MEK Signaling but not HIFa. PLoS Pathog 7:e1002088 (2011). WB, Flow Cyt; Human.Read more (PubMed: 21698228) »
  • Rades Det al. Prognostic impact of erythropoietin expression and erythropoietin receptor expression on locoregional control and survival of patients irradiated for stage II/III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 80:499-505 (2011). IHC-P; Human.Read more (PubMed: 20646855) »

See all 3 publications for this product

Publishing research using ab56310? Please let us know so that we can cite the reference in this datasheet

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"